The third important message of our study is that, yet not unexpectedly, we have found residual circulating CD26+LSC also in 66% of CML patients studied while in prolonged and stable TFR. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.